[COMPANY NAME] Ref.:EFORL020/2018 May 15, 2018 Subject: Management Discussion and Analysis for the first quarter ended 31 March 2018 To President The Stock Exchange of Thailand 1. Overview financial

[COMPANY NAME] Ref.: EFORL IR008/2019 March 7, 2019 Subject: Management Discussion and Analysis Yearly Ending 31 December, 2018 To President The Stock Exchange of Thailand 1. Overview financial

[COMPANY NAME] Ref.: EFORL IR 037/2018 August 15, 2018 Subject: Notification of allocation and subscription of capital increase ordinary shares of WCI Holding Public Company Limited. (Edit) To: The

that will support continuous growth momentum in demand for medical devices in Thailand. In 2019, the Company has improved and increased the sales team to increase sales efficiency in distributor of

construction contract to construction in progress as significant. Liabilities As at September 30, 2018, the Company and its subsidiaries had total liabilities of Baht 3,600.78 million increased from Baht

31, 2019 As at December 31, 2018 increase (decrease) Assets As at March 31, 2019, the Company and its subsidiaries had total assets of Baht 7,531.89 million increased from as of December 31, 2018 which

Assets As of June 30, 2020, the Company and its subsidiaries had total assets of Baht 8,905.86. million increased from Baht 8,553.07 million as of December 31, 2019 of Baht 352.79 million or 4.12

) Interest bearing debt to equity ratio 1.21 1.03 Debt to equity ratio 1.35 1.16 Assets As of March 31, 2020, the Company and its subsidiaries had total assets of Baht 8,884.56 million increased from Baht

[COMPANY NAME] EFORL IR010/2018 March 20, 2018 Subject: Management Discussion and Analysis Yearly Ending 31 December, 2017 To President The Stock Exchange of Thailand 1. Overview financial

Company Profile - DOD BIOTECH PUBLIC COMPANY LIMITED สำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ Printed on 28 August 2022 21:45 ​ ​ Company Profile DOD BIOTECH PUBLIC COMPANY LIMITED Please